VALN — Valneva SE Stock Price, Chart & AI Report

Negative Feb 6, 2026 • 07:30 UTC GlobeNewswire Inc. • Na

VALNEVA Déclaration d’actions et de droits de vote : 31 janvier 2026

Valneva has voluntarily withdrawn its IXCHIQ chikungunya vaccine BLA (Biologics License Application) and IND (Investigational New Drug) in the United States. The company is continuing to review global product opportunities based on medical need and commercial attractiveness. This decision comes as Valneva and Instituto Butantan announced initiation of a pilot vaccination campaign in Brazil with the single-shot vaccine.

VALN chikungunya vaccine IXCHIQ BLA withdrawal IND withdrawal Brazil pilot campaign Instituto Butantan

Sentiment note

The voluntary withdrawal of the BLA and IND applications in the U.S. represents a setback for the company's primary market expansion strategy. This indicates regulatory or commercial challenges with the vaccine in the U.S., though the company is pursuing alternative markets like Brazil.

Negative Feb 6, 2026 • 07:30 UTC GlobeNewswire Inc. • Na

VALNEVA Declaration of shares and voting rights: January 31, 2026

Valneva has voluntarily withdrawn its Biologics License Application (BLA) and Investigational New Drug (IND) for IXCHIQ chikungunya vaccine in the United States. Simultaneously, the company is advancing a pilot vaccination campaign with Instituto Butantan in Brazil, continuing to evaluate the global product opportunity based on medical need and commercial attractiveness.

VALN chikungunya vaccine IXCHIQ BLA withdrawal clinical development Brazil vaccination campaign Instituto Butantan

Sentiment note

The voluntary withdrawal of the BLA and IND in the U.S. represents a setback for the company's primary market expansion strategy. However, the sentiment is mitigated by continued development efforts in Brazil and the company's strategic reassessment of global opportunities, suggesting a pivot rather than complete abandonment of the product.

Positive Dec 5, 2025 • 17:34 UTC GlobeNewswire Inc. • Valneva Se

VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025

Valneva is consolidating its French operations at its Lyon site and finalizing R&D consolidation in Vienna. The company also reported positive Phase 2 results for its Lyme Disease vaccine candidate, showing sustained antibody levels and no safety concerns.

VALN vaccine Lyme disease operational consolidation R&D clinical trials

Sentiment note

Positive Phase 2 vaccine trial results, strategic operational consolidation, and continued research and development efforts indicate company growth and progress

Neutral Dec 5, 2025 • 17:34 UTC GlobeNewswire Inc. • Valneva Se

VALNEVA Declaration of shares and voting rights: November 30, 2025

Valneva reported changes in its share capital and voting rights, including the issuance of new ordinary shares through stock option exercises and transfers of shares between November 6-28, 2025.

VALN shares voting rights stock options capital

Sentiment note

The document is a routine financial disclosure reporting standard changes in share capital and voting rights, with no significant positive or negative indicators

Positive Nov 5, 2025 • 17:00 UTC GlobeNewswire Inc. • Valneva Se

VALNEVA Déclaration d’actions et de droits de vote : 31 octobre 2025

Valneva reported positive results from a Phase 1 trial of its second-generation Zika vaccine candidate, demonstrating an improved immune response compared to previous iterations.

VALN Zika vaccine Phase 1 trial immune response vaccine development

Sentiment note

Successful improvement of immune response in vaccine trial indicates promising research progress and potential future commercial viability

Neutral Nov 5, 2025 • 17:00 UTC GlobeNewswire Inc. • Valneva Se

VALNEVA Declaration of shares and voting rights: October 31, 2025

Valneva reported changes in its share capital and voting rights, with a total of 171,958,275 ordinary shares and 187,722,356 net voting rights after transfers and free share attributions.

VALN shares voting rights capital transfer free shares

Sentiment note

The article describes routine financial reporting of share and voting rights changes without indicating significant positive or negative business developments

Neutral Oct 6, 2025 • 05:30 UTC GlobeNewswire Inc. • Na

VALNEVA Declaration of shares and voting rights: September 30, 2025

Valneva reported a change in its share composition, with 171,854,856 ordinary shares and a transfer of 653 shares with double voting rights between September 1-18, 2025.

VALN shares voting rights financial disclosure

Sentiment note

Standard financial reporting of shares and voting rights with no significant positive or negative indicators

Neutral Oct 6, 2025 • 05:30 UTC GlobeNewswire Inc. • Na

VALNEVA Déclaration d’actions et de droits de vote : 30 septembre 2025

Valneva reported its shares and voting rights status as of September 30, 2025, with 171,854,856 ordinary actions and 187,978,646 total voting rights, noting minor changes in share ownership and voting rights.

VALN shares voting rights financial declaration Euronext Paris

Sentiment note

Standard financial reporting with no significant positive or negative indicators, routine disclosure of corporate shareholding status

Positive Oct 1, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight

DelveInsight's analysis predicts growth in the Lyme disease market from 2025-2034, driven by emerging therapies and increased healthcare spending, with new vaccine and prevention technologies in development.

VALN PFE TARS MRNA Lyme disease vaccine healthcare market growth

Sentiment note

Developing VLA15 vaccine, most advanced Lyme disease vaccine candidate with FDA Fast Track Designation

Negative Sep 24, 2025 • 20:39 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

Pomerantz LLP is investigating potential securities fraud by Valneva related to its chikungunya virus vaccine IXCHIQ, following CDC hospitalizations and FDA marketing application suspension.

VALN vaccine securities fraud CDC FDA investigation

Sentiment note

Stock price dropped 13.57% after CDC announced hospitalizations, and another 18.99% when FDA suspended marketing application due to safety concerns for IXCHIQ vaccine

Negative Sep 18, 2025 • 21:56 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential securities law violations by Valneva after CDC and FDA raised safety concerns about its chikungunya virus vaccine IXCHIQ, leading to significant stock price drops.

VALN vaccine CDC FDA safety investigation securities law

Sentiment note

Stock experienced multiple price drops due to safety concerns about its vaccine, with CDC investigating hospitalizations and FDA suspending marketing application, indicating significant regulatory and potential legal challenges

Negative Sep 11, 2025 • 21:59 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

FORTINET ALERT: Bragar Eagel & Squire, P.C. is Investigating Fortinet, Inc. on Behalf of Fortinet Stockholders and Encourages Investors to Contact the Firm

Law firm investigating Fortinet after disappointing Q2 2025 financial results, with stock price dropping 22.03% following analyst confusion about product revenue growth and firewall refresh.

FTNT VALN FUN securities investigation financial performance stock price firewall technology

Sentiment note

ADRs fell 13.6% in February and 19% in August 2025 due to safety issues with IXCHIQ vaccine